JUPITER-06研究确立了免疫检查点抑制剂作为晚期食管鳞状细胞癌一线治疗的基础用药地位。
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma.
作者信息
Yamamoto Shun, Kato Ken
机构信息
Department of Head and Neck Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Department of Head and Neck Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
出版信息
Cancer Cell. 2022 Mar 14;40(3):238-240. doi: 10.1016/j.ccell.2022.02.009. Epub 2022 Mar 3.
The phase III JUPITER-6 trial showed superior progression-free survival and overall survival for toripalimab plus chemotherapy, compared with chemotherapy alone, in previously untreated patients with advanced esophageal squamous cell carcinoma. This provides solid evidence that immune checkpoint inhibitors are key drugs for the first-line treatment of advanced esophageal squamous cell carcinoma.
III期JUPITER-6试验表明，对于先前未接受过治疗的晚期食管鳞状细胞癌患者，与单纯化疗相比，托瑞帕利单抗联合化疗可显著提高无进展生存期和总生存期。这为免疫检查点抑制剂作为晚期食管鳞状细胞癌一线治疗的关键药物提供了确凿证据。
Zotero 插件